Group 1: Fund Performance - Summers Value Fund LP achieved a net return of 20.4% in Q3 2025, outperforming the Russell 2000 Index ETF and the Russell 2000 Value Index ETF, which returned 12.4% and 12.5% respectively [1] - Year-to-date, the fund is up 4.9%, while the Russell 2000 Index ETF and the Russell 2000 Value Index ETF have returns of 10.3% and 8.9% respectively [1] Group 2: UniQure N.V. Overview - UniQure N.V. (NASDAQ:QURE) is a biotechnology company focused on developing treatments for rare diseases, with a one-month return of -50.41% and a 52-week gain of 421.23% [2] - As of November 18, 2025, UniQure N.V. shares closed at $29.71, with a market capitalization of $1.851 billion [2] Group 3: Investment Position in UniQure N.V. - The fund initiated a position in UniQure N.V. following positive Phase 3 results for its gene therapy drug in Huntington's Disease, which demonstrated a 75% reduction in disease progression [3] - The fund held twelve long positions and no shorts at the end of the quarter, sizing the position in UniQure N.V. appropriately due to its early stage of development [3] Group 4: Hedge Fund Interest and Revenue - At the end of Q2 2025, 36 hedge fund portfolios held UniQure N.V., an increase from 35 in the previous quarter [4] - UniQure N.V. reported $3.7 million in revenue for Q3 2025, up from $2.3 million in Q3 2024 [4]